Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/6/2025 | $23.00 | Buy | D. Boral Capital |
| 9/8/2023 | $14.50 | Buy | Alliance Global Partners |
| 1/5/2023 | $21.00 | Overweight | Cantor Fitzgerald |
6-K - Nano-X Imaging Ltd. (0001795251) (Filer)
6-K - Nano-X Imaging Ltd. (0001795251) (Filer)
6-K - Nano-X Imaging Ltd. (0001795251) (Filer)
Agreement with Imperial Imaging strengthens Nanox's commercial rollout across the orthopedic-rich segment in six U.S. Southeast states. Distribution Agreement Supports U.S. Market Expansion PETACH TIKVA, Israel, March 03, 2026 (GLOBE NEWSWIRE) -- Nano-X Imaging Ltd. (NASDAQ:NNOX), a leader in innovative medical imaging technology, today announced that its US-based subsidiary, Nanox Impact Inc. has signed a new distribution agreement with Imperial Imaging Technology LLC, a Georgia based provider of diagnostic imaging solutions. The collaboration will support the commercial rollout of the Nanox.ARC, a multisource digital tomosynthesis system that makes 3D imaging possible in more clinica
Collaboration with Intec SRL drives commercial expansion of 3D medical imaging across a high-growth private healthcare market PETACH TIKVA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Nanox Imaging Ltd. (("Nanox", NASDAQ:NNOX), a leader in innovative medical imaging technology, today announced a distribution agreement with Intec SRL, an Argentina-based medical device distributor with more than 35 years of experience delivering advanced imaging technologies to healthcare providers nationwide. The Nanox.ARC is a multi-source digital tomosynthesis system that makes 3D imaging possible in more places, at a lower cost and with significantly reduced radiation dose than traditional CT. Digital to
Live demonstrations of the Nanox.ARC will feature at the ECR booth #425 in Hall X4Oral presentation by Dr. Nogah Shabshin to present data on potential role of digital tomosynthesis in lung cancer screeningOral presentation by Dr. Orit Wimpfheimer to explore how Nanox AI transforms routine CT scans into tools for early detection of cardiovascular disease, osteoporosis and fatty liver diseasePoster presentations to highlight new clinical data from ADOPT study featuring AI bone solution PETACH TIKVA, Israel, Feb. 17, 2026 - NANO-X IMAGING LTD (("Nanox" or the "Company", NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will showcase its Nanox.ARC digital t
4 - Nano-X Imaging Ltd. (0001795251) (Issuer)
4 - Nano-X Imaging Ltd. (0001795251) (Issuer)
3 - Nano-X Imaging Ltd. (0001795251) (Issuer)
D. Boral Capital initiated coverage of Nano-X Imaging with a rating of Buy and set a new price target of $23.00
Alliance Global Partners initiated coverage of Nano-X Imaging with a rating of Buy and set a new price target of $14.50
Cantor Fitzgerald initiated coverage of Nano-X Imaging with a rating of Overweight and set a new price target of $21.00
NEVE ILAN, Israel, May 03, 2021 (GLOBE NEWSWIRE) -- NANOX IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, announced today the appointment of Moshe Shtengel as Chief Business Officer, effective May 2, 2021. Mr. Shtengel joins Nanox from Tuttnauer, a global manufacturer of sterilizers and infection control systems for medical institutions, where he served as Vice President of Global Sales, Marketing and Products. "Moshe is an extremely seasoned sales and business development executive with a proven track record of success and leadership in the medical field," stated Ran Poliakine, Chairman and Chief Executive Officer of Nanox. "As we
Management to host conference call and webcast Thursday, November 20, 2025, at 8:30 AM ET Company advances commercialization and is on track to meet year-end system deployment target PETAH TIKVA, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, today announced results for the third quarter ended September 30, 2025, and provided a business update. Recent Highlights: Generated $3.4 million in revenue in the third quarter of 2025, compared to $3.0 million in the third quarter of 2024.Acquired 100% of the stock of Vaso Healthcare IT, a provider of healthcare information technologies solu
PETACH TIKVA, Israel, Nov. 07, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended September 30, 2025, before market open on Thursday, November 20, 2025. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q3 2025 Conference Call. The live webcast of the conference call may be ac
Management to host conference call and webcast Tuesday, August 12, 2025 at 8:30 AM ET Company continued to grow Nanox.ARC installed base and is on track to meet its year-end system deployment target PETAH TIKVA, Israel, Aug. 12, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, today announced results for the second quarter ended June 30, 2025 and provided a business update. Recent Highlights: Generated $3.0 million in revenue in the second quarter of 2025, compared to $2.7 million in the second quarter of 2024.Grew Nanox.ARC system sales funnel exponentially in the quarter.The Company notified the FD
SC 13G/A - Nano-X Imaging Ltd. (0001795251) (Subject)
SC 13G - Nano-X Imaging Ltd. (0001795251) (Subject)
SC 13G/A - Nano-X Imaging Ltd. (0001795251) (Subject)